Biogen Inc BIIB

$252.26 +1.57 (0.63%)

Valuation

Market cap
37,040,444,000
Revenue TTM
$9,890,600,000
Net income TTM
$1,292,900,000
PE ratio
18.17
Forward PE
20.65
Profit margin
13.07%
Debt to equity
0.39

Trading

Volume
958,800
Avg volume
1,037,012
Day's range
$249.61 – $254.11
Shares out
147,754,000
Stochastic %K
92%
Beta
0.09
Analysts
Strong Sell
Price target
$246.39

Price

Company profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etan...

Show more

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
617 679 2000
Website
https://www.biogen.com
Address
225 Binney Street, Cambridge, United States

Latest news

Stocktwits

11thestate Oct 26, 3:37 PM
Biogen Finally Agreed to Settle With Investors over Aducanumab Clinical Trial Claims The case centered on claims that Biogen misled investors about clinical trial results for its Alzheimer’s drug, aducanumab. In November 2020, an FDA advisory committee voted 10-0 that the trial data did not support the drug’s effectiveness, and $BIIB fell 28.2% when trading resumed. So if you purchased $BIIB between 2019 and 2020, you may be eligible to submit your claim: https://11th.com/cases/biogen-investor-settlement
0 replies
zampy Oct 26, 1:22 PM
$COYA $RDY date Dec 22nd 2026 for Abatacept. This is the operational catalyst that puts all the supply and regulatory pieces in place. R.A. is on $RDY website for abtacept and others but that is a mature market. $RDY can not do the neuro market soley $COYA has the IL2 component that makes it all work for Tregs. $RDY can lock up the treg platform now or they can wait for potential SUITORS i.e. $SNY $LLY or $BIIB to come into the VDR during OLE.
0 replies
zampy Oct 24, 6:05 PM
$COYA I believe most do not understand what $COYA has here. The stock is an F however the company and management assembled here is an AAA+. Most deals happen in this space at their nadir's. 50% OF THE STOCK IS VIRTUALLY CASH WHICH IS INDANE WHERE WE ARE AT. No brainer for $LLY or $BIIB to come in. $RDY can get out of theit 670m plus royalties owed to us by buying us at $12 cash, esoecially with their stock climbing at $13.30 up 1.8b in mkt cap in 10 weeks. 833m o/s + $COYA o/s 23.5m = 858m o/s. Less then 3% dilution to $RDY ....at $12 290m less 43m cash $COYA 250M THEY SAVE OVER 450M OVER 8 YEARS..Seems like a no brainer to me and get FTD with CVR'S potential 4.5b to 6.5b..... This is not so complicated 250m deal and they steal FTD fir some CVR'S which is the same mechanism as ALS.
1 replies
NolAsrtormZ Oct 24, 3:30 PM
$ANVS Only 2 other public tradable companies reporting phase 3 Alzheimers data in 2027 All of which both have Billion $$$ market caps $BIIB 37 billion aprx $LLY 1.2 Trillion 😛 Then there is $ANVS market cap of 42 million aprx
1 replies
investpapaya Oct 23, 9:27 AM
$AMGN and $BIIB absolute beasts! Its all about their pipelines, strategic positioning in global context, and reliable business strength. Investors now are eager to put their money on the future winners across all sectors. These are my top large cap healthcare picks.
0 replies
ivanhoff Oct 22, 2:50 PM
Heathcare stocks continue to dominate the 52-week relative-strength list - $LLY $BIIB $AMGN
0 replies
WAJeff Oct 22, 2:15 PM
$BIIB 246.54 52 week high, grinding higher
0 replies
Quantumup Oct 20, 3:33 PM
Truist reiterated $SRRK Buy-$77 and said -- SMA KOLs say 80% pts interested in Isembyld, expect 50-60% pts to be on drug in 5yrs; fractures not limiting $BIIB IONS RHHBY $NVS VYGR ARGX Truist added—We reiterate Buy on SRRK after KOL feedback supporting broad Isembyld uptake, with two KOLs guiding to ~60% and ~50% SMA patient penetration in five years. KOLs validated SAPPHIRE, highlighting ~33% responder rate at >=3 points and real function (rolling, feeding, sitting). Both would prescribe broadly, favoring earlier patients, with ~80% patient interest cited. KOLs to watch fracture risk but don't view it as limiting; expect most neurologists to skip DEXA. On reimbursement, KOLs see potential for some pushback early on in launch, but expect drug to be covered, as seen with other SMA drugs. Both were skeptical on FSHD but flagged combo potential with disease modifiers.
0 replies